한빛사논문
Byung-Woo Yoo1, Jason Jungsik Song1,2, Yong-Beom Park1,2, Sang-Won Lee1,2,*
1 Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
2 Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, South Korea
*Correspondence to
Professor Sang-Won Lee, Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Korea (the Republic of);
Abstract
We read with interest the original article by Wallace et al proposing the new classification for IgG4-related disease (IgG4-RD). We assessed the agreement rate between the comprehensive and the 2019 American College of Rheumatology and the European League Against Rheumatism classification criteria (the 2019 ACR/EULAR criteria) in patients previously diagnosed with definite IgG4-RD based on the comprehensive diagnostic criteria and investigated factors contributing to the reclassification of IgG4-RD. We applied the 2019 ACR/EULAR criteria to 40 patients with previously diagnosed with definite IgG4-RD (mean age: 60.2 years) and reviewed the clinical, laboratory and radiologic data and the histopathologic features with immunostaining. Ten patients (25.0%) showed no informative histopathologic features of IgG4-RD compatible with the 2019 ACR/EULAR criteria. Due to an exclusive condition on the lymph node biopsy samples, 5 patients were assigned no points in the immunostaining scores, despite clear evidence of IgG4+ cell infiltration. Finally, 1 of 40 patients (2.5%) was not reclassified as having IgG4-RD according to the 2019 ACR/EULAR criteria. In conclusion, the agreement rate between the comprehensive and the 2019 ACR/EULAR criteria was as high as 97.5% in patients previously diagnosed with definite IgG4-RD. The biopsy result of the lymph nodes without typical histopathologic and radiologic features based on the 2019 ACR/EULAR criteria was a negative factor in the reclassification of IgG4-RD.
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기